With two exon 53 skippers already approved for Duchenne muscular dystrophy (DMD), any new candidate was going to have to post remarkable data in order to have a chance of competing. Fortunately for Wave Life Sciences Ltd., WVE-N531 has done just that, and the company’s NASDAQ-listed shares soared by 53% to close at $8.19 on 24 September.
Key Takeaways
- Interim Phase II data on Wave Life Sciences’ WVE-N531 suggests it boosts dystrophin expression in Duchenne muscular dystrophy patients, potentially teeing up accelerated approval.
Interim data from 11 boys enrolled in the open-label FORWARD-53 trial show impressive efficacy for WVE-N531 after six months’ treatment....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?